CRP and metabolic syndrome: Further adjustment for VFA (model 3), VFA and CRP (model 4), HOMA-IR (model 5), or TG and HDL-c (model 6) only slightly reduced the magnitude of the association of baseline fractalkine with the development of MetS (OR = 5.31, 95% CI: 1.65–14.09 for model 3, OR = 5.17, 95% CI: 1.60–13.74 for model 4, OR = 5.73, 95% CI: 1.79–14.34 for model 5, and OR = 5.94, 95% CI: 1.85–15.09 for model 6).